“Tirzepatide has established human outcome evidence for defined metabolic indications.”

Supported with scope

The reviewed evidence supports this exact statement only in the situation described below.

Posted product labels, an August 2026 FDA approval letter, and large randomized trials support specific blood-sugar, weight, and cardiovascular findings in defined populations. The cardiovascular risk-reduction use belongs to Mounjaro.

What this answer is based on

This answer uses a study that assigned people to groups by chance and measured a health outcome.

Limits of this answer

The labeled and trial populations, outcomes, comparators, and durations for Mounjaro and Zepbound. Mounjaro's heart-risk use was approved August 27, 2026. These limits show which substance, product, people, use, place, and time the answer covers. A different product or situation can have a different answer.

Topic

What a study measured about people's health, symptoms, or ability to function.